Arthex Biotech S.L. is a biotechnology company based in Paterna, Spain, that specializes in the development of antisense RNA therapies for genetic diseases. Founded in 2019 as a spin-off from the University of Valencia, the company focuses on addressing unmet medical needs through innovative treatments targeting microRNAs, which are implicated in various disorders, including neuromuscular diseases. With a team experienced in drug discovery and strong support from leading scientific and clinical advisors, Arthex Biotech aims to provide effective therapies for patients suffering from rare and challenging conditions.
ATXA Therapeutics Limited is a pharmaceutical company based in Dublin, Ireland, focused on developing novel small molecule drugs for the treatment of pulmonary arterial hypertension (PAH). Established in 2015 as a spin-out from University College Dublin, the company has leveraged over 20 years of research and more than €15 million in grant funding to advance its clinical trials and secure marketing authorization for its therapies. ATXA's innovative approach involves targeting human thromboxane receptors to enhance vasodilation and reduce vasoconstriction, addressing significant unmet medical needs in PAH and other cardiovascular conditions. The team comprises experts in various fields, including cardiovascular and cancer biology, drug discovery, and preclinical pharmacokinetics, positioning ATXA to develop more effective treatments than current standard care options. The company aims to improve treatment outcomes for patients suffering from PAH and related conditions through its advanced therapies.
Protinhi Therapeutics is a preclinical stage biotechnology company focused on developing antiviral drugs to combat various viral threats, including dengue, Zika, and COVID-19. The company's innovative approach utilizes proprietary technology and compounds that target viral diseases through protease inhibition. This mechanism disrupts the viruses' ability to replicate, providing healthcare providers with a means to effectively control the spread of these infections. By concentrating on significant public health challenges, Protinhi Therapeutics aims to contribute to global efforts in managing and mitigating viral outbreaks.
CYTO365 is the manufacturer of RondelO multi inlet stopcock, which is sold as a component aimed to be integrated into IV-set to combat Drug Incompatibility due to parallel infusion.
Qu & Co is a developer of quantum-computational software focused on creating algorithms tailored for optimizing specialty chemicals, pharmaceuticals, and functional materials. The company's team of highly skilled quantum developers collaborates closely with clients and academic advisors to design innovative quantum algorithms and translate them into effective software solutions. Qu & Co's offerings enhance in-house discovery and optimization processes by advancing quantum-computational chemistry methods, seamlessly integrating with existing workflows in chemistry and material science. This enables clients in the pharmaceutical and other industries to conduct complex chemistry and multiphysics simulations on emerging quantum processors.
Qubit Pharmaceuticals, incorporated in 2020 and based in Paris, France, develops innovative technology aimed at enhancing pharmaceutical drug discovery. The company offers a drug discovery simulation platform that reduces the cost and duration of preclinical drug development. Utilizing proprietary force field models and molecular dynamics calculations, Qubit's platform conducts virtual screening and visualization to identify promising drug candidates. This approach leverages quantum physics to support biopharmaceutical companies in accelerating their research and development efforts.
Swiss Airtainer has developed a temperature-controlled container for the transport of pharmaceutical products by air.
Legacy Healthcare is a biopharma company focused on the development of oncology supportive care and dermatology drugs
Perha Pharmaceuticals is a biotechnology company dedicated to the research and development of innovative therapies aimed at addressing hearing loss and cognitive disorders. The company focuses on preventing cisplatin-induced hearing loss and developing treatments for cognitive conditions related to Down syndrome and Alzheimer's disease. Perha Pharmaceuticals leverages natural marine substances in its research, with chemists and biologists optimizing molecules derived from marine organisms to create effective kinase inhibitors. This approach underscores the company's commitment to advancing medical treatments and improving patient care in areas of significant unmet need.
Core Biogenesis is a biotechnology company building next-generation recombinant protein production technologies. The company uses proprietary gene editing and plant biotechnology to drastically reduce the cost of making growth factors. The growth factors are molecules used in the clean meat and cell therapy industries.
CH-Bioforce provides a revolutionary technology for converting all biomass components into high-value material streams - dissolving pulp, polymeric hemicellulose, and sulphur-free lignin. These valuable biomaterials can replace fossil and food-based raw materials in multiple industries, such as textiles and packaging applications.
Nagi Bioscience SA, based in Lausanne, Switzerland, specializes in the development and manufacturing of an innovative automated testing device that utilizes Caenorhabditis elegans, a type of microscopic worm, for the assessment of substances in pharmaceutical, chemical, and cosmetic industries. This technology, known as "Organism-on-Chip," integrates in vivo testing with a fully automated in vitro platform for handling, culturing, and analyzing these organisms. Nagi Bioscience's solutions facilitate toxicity testing, drug discovery, and anthelmintic testing, allowing clients to gain insights into the complete biological responses that can only be observed at the organism level. This approach aims to transform traditional methods of evaluating the toxic or beneficial effects of various substances.
Deasyl is identified, in-licence, and develops novel chemistry into scalable processes used by major fine chemical and petrochemical players.
Spartha Medical is a medical technology company focused on developing eco-friendly, invisible coatings designed for medical devices and consumer products to mitigate microbial and inflammatory risks. Utilizing natural biopolymers, the company’s innovative coatings possess antibacterial, antiviral, and anti-inflammatory properties, providing an effective solution for infection control. The technology relies on a patented method of supramolecular assembly, enabling precise control over the properties of the coatings based on specific applications. This approach allows for the creation of multifunctional and easy-to-apply surface treatments that help healthcare institutions maintain disease-free environments on medical devices.
Perha Pharmaceuticals is a biotechnology company dedicated to the research and development of innovative therapies aimed at addressing hearing loss and cognitive disorders. The company focuses on preventing cisplatin-induced hearing loss and developing treatments for cognitive conditions related to Down syndrome and Alzheimer's disease. Perha Pharmaceuticals leverages natural marine substances in its research, with chemists and biologists optimizing molecules derived from marine organisms to create effective kinase inhibitors. This approach underscores the company's commitment to advancing medical treatments and improving patient care in areas of significant unmet need.
Criam is a biotechnology company based in Braga, Portugal, founded in 2015, that focuses on developing medical devices for blood type analysis and disease detection. The company's flagship product, also named Criam, enables rapid and affordable blood test analysis, allowing users to receive immediate information about their health. This medical device can detect various diseases, including HIV, Brucella, tick fever, syphilis, mononucleosis, and meningitis. By positioning itself in the Point-of-Care diagnostic segment, Criam aims to empower individuals with timely health information and contribute to the global monitoring and control of diseases.
EVerZom is a nanomedicine biotech company providing a large scale of GMP manufacturing platform of extracellular vesicles. They develop a bioproduction platform to produce extracellular vesicles at a commercial scale in a GMP compliant way for pharmaceutical companies with applications in regenerative medicine and drug delivery. Extracellular vesicles that encompass exosomes, microvesicles, and apoptotic bodies are the tools used by cells to communicate with each other. EVerZom was founded in 2019 and is headquartered in Paris, Ile-de-France, France.
VarmX B.V., a biotechnology company, develops therapies in the field of hemostasis and thrombosis. It develops PseudoXa, a therapeutic protein that is used to stop bleeding of patients who use blood thinners. The company was founded in 2016 and is based in Leiden, the Netherlands.
VarmX B.V., a biotechnology company, develops therapies in the field of hemostasis and thrombosis. It develops PseudoXa, a therapeutic protein that is used to stop bleeding of patients who use blood thinners. The company was founded in 2016 and is based in Leiden, the Netherlands.
Genome Biologics are leaders in therapeutic target discovery and RNA-targeted therapies in cardiovascular and cardiometabolic disease. Our technology platforms seamlessly integrate synergistically to accelerate development of RNAi therapies to treat illnesses where no other treatments have proven effective or ever existed.
Palobiofarma S.L. is a biotechnology company based in Barcelona, Spain, with an additional facility in Navarra. Founded in 2005, the company specializes in the discovery and development of new drugs that target adenosine receptors, with a focus on treating advanced prostate cancer. By leveraging medicinal chemistry and in vitro pharmacology, Palobiofarma aims to be the first European company to market a selective adenosine receptor modulator, addressing significant medical needs through innovative therapeutic approaches.
Palobiofarma S.L. is a biotechnology company based in Barcelona, Spain, with an additional facility in Navarra. Founded in 2005, the company specializes in the discovery and development of new drugs that target adenosine receptors, with a focus on treating advanced prostate cancer. By leveraging medicinal chemistry and in vitro pharmacology, Palobiofarma aims to be the first European company to market a selective adenosine receptor modulator, addressing significant medical needs through innovative therapeutic approaches.
EpiEndo Pharmaceuticals is a privately held Icelandic pharmaceutical company developing a proprietary portfolio of compounds with epithelial barrier enhancing properties. EpiEndo is seed-funded, privately held and in preclinical development.EpiEndo is focusing on chronic respiratory diseases. First clinical trials are planned for the year 2019.EpiEndo is run as an international virtual organization coordinated by a team that consists of founding CEO Dr. Fridrik Runar Gardarsson and COO & CFO Birgir Magnusson, who coordinate a network of specialized service providers.
Xenothera SAS is a biotechnology company based in Nantes, France, focused on advancing immunological treatments through its innovative platform. Established in 2014, the company specializes in developing therapeutic solutions targeting various medical areas, including immunomodulation and infectious diseases. Its approach leverages proprietary Glyco-Humanized Antibodies and integrates expertise in animal genetics and immunology to create a new generation of hyperimmune polyclonal sera. By renovating passive immunotherapy, Xenothera aims to address unmet medical needs and facilitate the rapid development of new immunological therapies. The company's comprehensive platform allows for streamlined processes, from selecting immunogens to purifying immunoglobulins, ultimately aiming for expedited market authorization.
Xenothera SAS is a biotechnology company based in Nantes, France, focused on advancing immunological treatments through its innovative platform. Established in 2014, the company specializes in developing therapeutic solutions targeting various medical areas, including immunomodulation and infectious diseases. Its approach leverages proprietary Glyco-Humanized Antibodies and integrates expertise in animal genetics and immunology to create a new generation of hyperimmune polyclonal sera. By renovating passive immunotherapy, Xenothera aims to address unmet medical needs and facilitate the rapid development of new immunological therapies. The company's comprehensive platform allows for streamlined processes, from selecting immunogens to purifying immunoglobulins, ultimately aiming for expedited market authorization.
Roka Furadada mission is to reduce the incidence of skin cancer through research, development, and production of active ingredients and medical devices, with high efficiency and low toxicologic and environmental impact.
PROSION is a pharmaceutical & drug discovery start-up company.
Qubit Pharmaceuticals, incorporated in 2020 and based in Paris, France, develops innovative technology aimed at enhancing pharmaceutical drug discovery. The company offers a drug discovery simulation platform that reduces the cost and duration of preclinical drug development. Utilizing proprietary force field models and molecular dynamics calculations, Qubit's platform conducts virtual screening and visualization to identify promising drug candidates. This approach leverages quantum physics to support biopharmaceutical companies in accelerating their research and development efforts.
MedTrace Pharma A/S is a medical device company based in Kongens Lyngby, Denmark, with additional offices in Boston, Massachusetts, and Uppsala, Sweden. Founded in 2015, the company specializes in the development of innovative solutions for positron emission tomography (PET) imaging. Its flagship product, the MT-100, is an automated system designed for on-site production and infusion of the tracer 15O-water, which enhances the sensitivity of PET scans and improves patient throughput. MedTrace also offers aQuant, an analytical platform that interprets the PET scan results, enabling physicians to obtain accurate blood flow measurements in various clinical applications, including heart studies and tumor vascularization. The integration of these technologies aims to revolutionize PET diagnostic imaging by providing safer and more efficient tools for healthcare professionals.
EpiEndo Pharmaceuticals is a privately held Icelandic pharmaceutical company developing a proprietary portfolio of compounds with epithelial barrier enhancing properties. EpiEndo is seed-funded, privately held and in preclinical development.EpiEndo is focusing on chronic respiratory diseases. First clinical trials are planned for the year 2019.EpiEndo is run as an international virtual organization coordinated by a team that consists of founding CEO Dr. Fridrik Runar Gardarsson and COO & CFO Birgir Magnusson, who coordinate a network of specialized service providers.
Omnix Medical is dedicated to the development and commercialization of highly effective antibiotic agents against resistant pathogenic bacterial strains. Omnix is addressing an enormous and rapidly growing threat to public health, represented by millions worldwide, who suffer from infections associated with resistant bacteria. Omnix’s technology will tilt the odds in the battle against resistant bacteria and improve the lives of many people worldwide.
Omnix Medical is dedicated to the development and commercialization of highly effective antibiotic agents against resistant pathogenic bacterial strains. Omnix is addressing an enormous and rapidly growing threat to public health, represented by millions worldwide, who suffer from infections associated with resistant bacteria. Omnix’s technology will tilt the odds in the battle against resistant bacteria and improve the lives of many people worldwide.
Resistell is a antibiotic resistance test.
Faron is a clinical stage biopharmaceutical company developing novel treatments for medical conditions with significant unmet needs. The Company currently has a pipeline focusing on acute organ traumas, vascular damage and cancer immunotherapy.
Ilya Pharma AB is a biotechnology company based in Uppsala, Sweden, that specializes in developing biological drugs aimed at treating wounds in skin and mucosa. Founded in 2016, the company focuses on addressing both acute and chronic wounds, particularly those affecting individuals with diabetes. Ilya Pharma employs a unique approach by genetically modifying lactic acid bacteria, commonly found in yogurt, to produce substances that enhance the healing process of skin injuries. Their innovative drug delivery system utilizes these bacteria as vectors to administer biological drugs directly at the wound site or within the gastrointestinal tract, facilitating accelerated healing in a cost-effective manner. The company’s research and development efforts are rooted in extensive scientific studies conducted at Uppsala University and the Swedish University of Agriculture.
Ability Pharmaceuticals, S.L. is a clinical stage biopharmaceutical company based in Barcelona, Spain, dedicated to the discovery and development of human therapeutics for cancer and other unmet medical needs. The company specializes in creating Lipid Analogue Therapeutics, a novel class of small molecules designed to be administered orally. Its primary focus is on developing treatments for lung, pancreatic, and gynecological cancers. The development pipeline includes ABTL0812, which targets the Akt/mTOR signaling pathways, and ABTL0815, currently in preclinical characterization. Ability Pharmaceuticals develops its drug candidates up to clinical proof of concept before out-licensing them to pharmaceutical companies for further development. Founded in 2009, the company was formerly known as AB Therapeutics, S.L. and changed its name in September 2012.
Faron is a clinical stage biopharmaceutical company developing novel treatments for medical conditions with significant unmet needs. The Company currently has a pipeline focusing on acute organ traumas, vascular damage and cancer immunotherapy.
MedTrace Pharma A/S is a medical device company based in Kongens Lyngby, Denmark, with additional offices in Boston, Massachusetts, and Uppsala, Sweden. Founded in 2015, the company specializes in the development of innovative solutions for positron emission tomography (PET) imaging. Its flagship product, the MT-100, is an automated system designed for on-site production and infusion of the tracer 15O-water, which enhances the sensitivity of PET scans and improves patient throughput. MedTrace also offers aQuant, an analytical platform that interprets the PET scan results, enabling physicians to obtain accurate blood flow measurements in various clinical applications, including heart studies and tumor vascularization. The integration of these technologies aims to revolutionize PET diagnostic imaging by providing safer and more efficient tools for healthcare professionals.
ADmit Therapeutics, S.L. is a biotechnology company based in Begues, Spain, dedicated to the development of diagnostic tests for the early detection of Alzheimer’s disease. Founded in 2017, the company utilizes epigenetic analysis of blood samples to identify a series of mitochondrial biomarkers that are not related to traditional indicators such as ß-amyloid or tau proteins. By analyzing a large number of methylcytosines in mitochondrial DNA through next-generation sequencing, ADmit Therapeutics provides a novel and accessible method for medical practitioners to detect early-stage Alzheimer’s disease. Their innovative approach primarily serves pharmaceutical companies, aiming to enhance diagnostic capabilities in the field of neurodegenerative diseases.
Xenothera SAS is a biotechnology company based in Nantes, France, focused on advancing immunological treatments through its innovative platform. Established in 2014, the company specializes in developing therapeutic solutions targeting various medical areas, including immunomodulation and infectious diseases. Its approach leverages proprietary Glyco-Humanized Antibodies and integrates expertise in animal genetics and immunology to create a new generation of hyperimmune polyclonal sera. By renovating passive immunotherapy, Xenothera aims to address unmet medical needs and facilitate the rapid development of new immunological therapies. The company's comprehensive platform allows for streamlined processes, from selecting immunogens to purifying immunoglobulins, ultimately aiming for expedited market authorization.
Ability Pharmaceuticals, S.L. is a clinical stage biopharmaceutical company based in Barcelona, Spain, dedicated to the discovery and development of human therapeutics for cancer and other unmet medical needs. The company specializes in creating Lipid Analogue Therapeutics, a novel class of small molecules designed to be administered orally. Its primary focus is on developing treatments for lung, pancreatic, and gynecological cancers. The development pipeline includes ABTL0812, which targets the Akt/mTOR signaling pathways, and ABTL0815, currently in preclinical characterization. Ability Pharmaceuticals develops its drug candidates up to clinical proof of concept before out-licensing them to pharmaceutical companies for further development. Founded in 2009, the company was formerly known as AB Therapeutics, S.L. and changed its name in September 2012.
EpiEndo Pharmaceuticals is a privately held Icelandic pharmaceutical company developing a proprietary portfolio of compounds with epithelial barrier enhancing properties. EpiEndo is seed-funded, privately held and in preclinical development.EpiEndo is focusing on chronic respiratory diseases. First clinical trials are planned for the year 2019.EpiEndo is run as an international virtual organization coordinated by a team that consists of founding CEO Dr. Fridrik Runar Gardarsson and COO & CFO Birgir Magnusson, who coordinate a network of specialized service providers.
Hafnium Labs supports chemicals, energy, and pharma companies by solving one of the biggest challenges in chemistry: Obtaining reliable physical properties fast. From drugs that save our lives, to crop and energy technologies that will save our tomorrow, advances in chemistry change the world. By supporting researchers and engineers working with chemistry we help create a brighter future. We have developed a breakthrough system for combining state-of-the-art predictive methods, such as quantum chemistry and AI, with experimental physical property data. By intelligently and transparently using all available information, we provide the most accurate physical property predictions and quantify the uncertainty, so you know how reliable each prediction is. Our Q-props™ tools support decision making from molecular discovery to process optimization. Check out our website and reach out to learn more about how to use Q-props™ in your company.
EpiEndo Pharmaceuticals is a privately held Icelandic pharmaceutical company developing a proprietary portfolio of compounds with epithelial barrier enhancing properties. EpiEndo is seed-funded, privately held and in preclinical development.EpiEndo is focusing on chronic respiratory diseases. First clinical trials are planned for the year 2019.EpiEndo is run as an international virtual organization coordinated by a team that consists of founding CEO Dr. Fridrik Runar Gardarsson and COO & CFO Birgir Magnusson, who coordinate a network of specialized service providers.
S-Biomedic is a Belgian biotech company specializing in live probiotic cosmetics designed to improve skin health. The company focuses on the skin microbiome, a complex ecosystem of beneficial and harmful bacteria that plays a crucial role in skin conditions such as acne, eczema, rosacea, and aging. S-Biomedic employs advanced modulation-based technology to selectively harness beneficial bacteria, creating products that promote the rebalancing of the skin microbiome. By utilizing the latest advancements in microbiology and dermatology, their offerings aim to restore healthy skin and address various dermatological concerns. Through this innovative approach, S-Biomedic provides therapeutic solutions in both the dermatology and cosmetic sectors, enhancing the overall health and beauty of the skin.
Antofénol is a post-harvest biocontrol company focused on reducing losses in agricultural produce, particularly in viticulture. The company specializes in the ecological eco-extraction of plant matter, utilizing innovative techniques such as microwaves, ultrasonics, vacuum, and mixing to develop tailored chemical compositions. Antofénol offers services that include eco-extraction, anti-fungal testing, and biochemical characterization, allowing harvesters to effectively protect fruits and vegetables from fungal and mold infestations. Through its approach, Antofénol aims to valorize viticultural waste while promoting sustainable agricultural practices.